FY2025 Earnings Forecast for MREO Issued By Leerink Partnrs

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) – Research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research report issued to clients and investors on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.01) for the year, down from their prior estimate of $0.05. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q1 2026 earnings at $0.05 EPS and FY2026 earnings at $0.13 EPS.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.01) EPS for the quarter. The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $3.70 million.

Other analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mereo BioPharma Group in a research report on Wednesday, October 8th. Zacks Research cut Mereo BioPharma Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. boosted their price objective on shares of Mereo BioPharma Group from $7.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Finally, Wall Street Zen raised shares of Mereo BioPharma Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Mereo BioPharma Group Price Performance

MREO stock opened at $1.84 on Thursday. The company’s 50 day simple moving average is $1.91 and its 200-day simple moving average is $2.09. Mereo BioPharma Group has a 52-week low of $1.47 and a 52-week high of $4.21. The firm has a market capitalization of $292.56 million, a P/E ratio of -30.67 and a beta of 0.41.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. raised its position in Mereo BioPharma Group by 20.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 9,440,112 shares of the company’s stock worth $25,583,000 after purchasing an additional 1,620,249 shares in the last quarter. Aberdeen Group plc boosted its holdings in Mereo BioPharma Group by 82.9% in the third quarter. Aberdeen Group plc now owns 5,538,699 shares of the company’s stock valued at $11,410,000 after acquiring an additional 2,509,827 shares during the last quarter. 683 Capital Management LLC boosted its stake in shares of Mereo BioPharma Group by 1.9% in the 1st quarter. 683 Capital Management LLC now owns 4,635,000 shares of the company’s stock valued at $10,429,000 after purchasing an additional 85,000 shares during the last quarter. Tejara Capital Ltd raised its position in shares of Mereo BioPharma Group by 8.8% during the 1st quarter. Tejara Capital Ltd now owns 2,521,324 shares of the company’s stock valued at $5,673,000 after acquiring an additional 204,239 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Mereo BioPharma Group by 0.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock valued at $4,783,000 after acquiring an additional 6,068 shares during the period. Institutional investors and hedge funds own 62.83% of the company’s stock.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.